| Status | In progress |
| Process | HST |
| ID number | 1473 |
Provisional Schedule
| Committee meeting: 1 | 28 November 2019 |
| Expected publication | 03 June 2020 |
Project Team
| Project lead | Jo Ekeledo |
Email enquiries
- If you have any queries please email HST@nice.org.uk
Consultees
| Companies sponsors | AveXis |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Muscular Dystrophy UK |
| Spinal Muscular Atrophy UK (SMA UK) | |
| The Annabelle Rose Foundation for Spinal Muscular Atrophy | |
| TreatSMA | |
| Professional groups | Association of British Neurologists |
| British Society for Children's Orthopaedic Surgery | |
| Royal College of Pathologists | |
| Royal College of Physicians |
Commentators
| Comparator companies | Biogen |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 June 2019 | Invitation to participate |
| 03 June 2019 | In progress, To evaluate the benefits and costs of onasemnogene abeparvovec within its marketing authorisation for treating spinal muscular atrophy type 1 for national commissioning by NHS England |
| 06 November 2018 (10:00) | Scoping workshop (Manchester) |
| 19 September 2018 - 17 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance